Compare Neurocrine Biosciences Inc (NBIX) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Stanley Black & Decker, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Stanley Black & Decker, Inc. trades at $88.57 (market cap $13.47B). The key difference: Neurocrine Biosciences Inc and Stanley Black & Decker, Inc. are close in size by market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| NBIX | SWK | |
|---|---|---|
Market Cap | $14.36B | $13.47B |
Volume | 1,237,180 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $185.50 | $104.00 |
52-Week Low | $123.10 | $62.12 |
Typical Hold Time | 23 Days | 62 Days |
Enterprise Value | $14.37B | $17.63B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Stanley Black & Decker (SWK) trades at $89.17, up 0.97% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin rising to 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89, while analyst consensus leans neutral with 43% buy ratings and $93 price target.
SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness and competitive pressures. The stock offers value characteristics with dividend stability but faces execution risks in achieving projected earnings growth. Near-term direction will depend on Q3 2026 results due November 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
